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ABSTRACT
Background: The European Organization for Research and Treatment of Cancer (EORTC) 62012 study
was a Phase III trial of doxorubicin versus doxorubicin–ifosfamide chemotherapy in 455 patients with
advanced soft tissue sarcoma (STS). Analysis of the main study showed that combination chemother-
apy improved tumor response and progression-free survival, but differences in overall survival (OS)
were not statistically significant. We analyzed factors prognostic for tumor response and OS, and
assessed histological subgroup and tumor grade as predictive factors to identify patients more likely to
benefit from combination chemotherapy.
Methods: Central pathology review was performed by six reference pathologists. Gender, age, per-
formance status, time from first presentation with sarcoma to starting palliative chemotherapy, tumor
grade, histological subgroup, primary tumor site involvement, and sites of metastases were assessed as
prognostic factors.
Results: Three hundred and ten patients were included in this study. Discordance between local and
central pathology opinion of tumor histology and tumor grade was observed in 98 (32%) and 122
(39%) cases, respectively. In multivariate analysis, liposarcoma patients had improved tumor response
compared to other histological subgroups, whilst patients with metastases other than lung, liver or
bone had a poorer response [odds ratio (OR) 0.42, 95% confidence interval (CI) 0.23–0.78; p¼ 0.006].
Patients with bone metastases had reduced OS [hazard ratio (HR) 1.56, 95% CI 1.16–2.09; p¼ 0.003]. By
central pathology review, patients with undifferentiated pleomorphic sarcoma (UPS) had improved
tumor response and OS with doxorubicin–ifosfamide compared to single-agent doxorubicin (OR 9.90,
95% CI 1.93–50.7 and HR 0.44, 95% CI 0.26–0.79, respectively). Grade III tumors had improved response
with combination chemotherapy but there was no interaction between chemotherapy and grade
on OS.
Conclusions: Prospective central pathology review of tumor histology should be integrated into future
STS clinical trials. Doxorubicin–ifosfamide may be most appropriate for young, fit patients with poorly
differentiated Grade III tumors including UPS.
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Introduction
Soft tissue sarcomas (STS) are a group of rare aggressive
tumors of mesenchymal origin, separated into over 50 differ-
ent subtypes by histological and molecular classifications
[1,2]. Chemotherapy is the mainstay of treatment for patients
with unresectable metastatic disease, and is usually adminis-
tered with palliative intent. Doxorubicin and ifosfamide have
single-agent activity in STS [3,4], but the role of doxorubici-
n–ifosfamide combination has been less certain. The
European Organization for Research and Treatment of Cancer
(EORTC) 62012 study was a multi-centre randomized Phase III
trial of first-line single-agent doxorubicin versus intensified
doxorubicin–ifosfamide chemotherapy for young, fit patients
with advanced intermediate or high-grade STS [5].
Combination chemotherapy was associated with a signifi-
cantly higher tumor response rate (completeþpartial
response, 26 versus 14%; p< .0006) and improved progres-
sion-free survival [PFS, hazard ratio (HR) 0.74, 95% confidence
interval (CI) 0.60–0.90; p¼ .003], but overall survival (OS) was
not significantly different (HR 0.83, 95% CI 0.67–1.03;
p¼ .076). Furthermore, combination chemotherapy was asso-
ciated with significantly more toxicity (Grade 3–4 febrile neu-
tropenia 46 versus 13%; p< .0001). The study authors
concluded that single-agent doxorubicin was appropriate for
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the majority of patients with advanced STS; however, com-
bination chemotherapy was justified for select patients in
whom the primary aim of treatment was tumor shrinkage, to
alleviate symptoms or to enable local disease control by sub-
sequent surgery or radiotherapy.
A previous meta-analysis of seven heterogeneous
EORTC-led clinical trials of first-line anthracycline-based
chemotherapy for advanced STS-reported younger age, good
performance status (PS) and absence of liver metastases as
prognostic of both improved tumor response to chemother-
apy and OS [6]. Higher tumor grade and liposarcoma hist-
ology were other factors associated with improved tumor
response to chemotherapy, whilst low tumor grade and lon-
ger time elapsed from initial diagnosis of sarcoma to starting
first-line chemotherapy were associated with improved OS.
We performed an analysis of the EORTC 62012 study to
validate factors prognostic of tumor response to chemother-
apy and OS in patients with advanced STS treated in a con-
temporary prospective randomized Phase III clinical trial. We
then explored histological subtype and tumor grade as pre-
dictive factors to identify patient subgroups more likely to
benefit from treatment with combination chemotherapy.
Methods
Patients included in the subgroup analysis
Four hundred and fifty-five patients were recruited to the
EORTC 62012 study (NCT00061984). The detailed eligibility
criteria for the EORTC 62012 study have previously been pub-
lished [5], including age 60 years, WHO PS 0 or 1, and inter-
mediate or high-grade STS by local pathology opinion.
Patients who received at least one cycle of chemotherapy
were eligible for the subgroup analysis. A central pathology
review of tumor histology and tumor grade was mandated in
the trial protocol and performed by six expert STS patholo-
gists according to the World Health Organization 2013 classi-
fication of tumors of soft tissue and bone [1] and the French
Federation Nationale des Centres de Lutte Contre le Cancer
(FNCLCC) system [7], respectively. Cases without central path-
ology review, or without sarcoma histology, or where tumor
grade was low or not assessable by central pathology review,
or who did not meet other eligibility criteria for the main
study were excluded (Figure 1). The study population thereby
consisted of 310 patients with characteristics broadly similar
to the main study population (Table 1).
Histological subtypes were pooled for analysis into liposar-
coma, leiomyosarcoma, synovial sarcoma, undifferentiated
pleomorphic sarcoma (UPS) or ‘other’ subgroups. Gender,
age, PS, time elapsed from initial presentation with sarcoma
to starting palliative chemotherapy, tumor grade, histological
subgroup, primary tumor site involvement and site of meta-
stases (liver, lung, bone and ‘other’) were assessed as factors
prognostic for tumor response to chemotherapy and OS.
Patients were included in the prognostic factor analysis
based on central pathology review.
Histological subgroup and tumor grade were then
assessed as factors predictive of improved tumor response
and OS with combination chemotherapy. In this exploratory
analysis, histological subgroup and tumor grade were ana-
lyzed according to both local and central pathology
assignment.
Statistics
Response to chemotherapy was reported based on local
investigator assessment according to RECIST 1.0 [8]. OS
was computed from the date of randomization in the
study to the date of death. Patients still alive at the time
of the analysis were censored at their last follow-up date
or the clinical trial cut-off date, whichever occurred first.
Analyses for response rate (completeþpartial response)
were performed using logistic regression; analyzes for OS
were performed using Cox regression models. Factors
included in the final multivariate models were identified
using stepwise selection. A significance level of 0.15 was
required to include a factor in the multivariate model, and
a significance level of 0.05 was required for a factor to
stay in the model.
Results
Central pathology review of tumor histology was available
for 354/455 cases (78%). Discordance with local assessment
EORTC 62012 
N = 455
Eligible
N = 310 (68%)
Not eligible
N = 145 (32%)
Did not start study 
treatment 
N = 3
Central histology 
review missing
N = 101
Not sarcoma on 
histology
N = 6
Low grade/grade 
not assessable
N = 29
Failed other 
eligibility criteria
N=6
Figure 1. Subgroup analysis flow chart.
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was observed in 118 cases (33%), including six patients who
did not have STS histology on central review. Central path-
ology review of tumor grade was available for 339/455 cases
(75%). Discordance with local assessment was observed in
141 cases (42%). After excluding patients that failed other eli-
gibility criteria, 310 patients were included in the subgroup
analysis. Of these 310 patients, discordance between local
and central pathology assessment of tumor histology and
tumor grade was observed in 98 (32%) and 122 (39%) cases,
respectively. Consistent with the main study results, combin-
ation chemotherapy was associated with improved tumor
response [odds ratio (OR) 2.44, 95% CI 1.38–4.31; p¼ .002],
but OS was not significantly different (HR 0.82, 0.64–1.04;
p¼ .105).
Prognostic factor analysis
In multivariate analysis, gender, age, PS, time from first pres-
entation with sarcoma to starting palliative chemotherapy,
tumor grade, histological subgroup, primary tumor site
involvement, and sites of metastases were assessed as poten-
tial factors prognostic for tumor response to chemotherapy
and OS. Central pathology review of histology and tumor
grade were used for this analysis.
In multivariate analysis, liposarcoma histology and ‘other’
metastatic disease sites were prognostic for tumor response
to chemotherapy (Table 2). Patients with liposarcoma had
improved tumor response to chemotherapy compared to
other histological subgroups (overall p¼ .014). The lungs are
the most common site of metastases for patients with STS,
and in this analysis were present in 227/310 (73.2%) cases
(Table 1). Sites of metastatic disease other than lung, liver
and bone were involved in 185/310 (59.7%) cases, and
included lymph node metastases (92 cases), skin metastases
(9 cases) and other soft tissue metastases (77 cases). Patients
with metastases present at ‘other’ sites had poorer tumor
response to chemotherapy compared to patients that did
not (OR 0.42, 95% CI 0.23–0.78; p¼ .006). Grade III tumors
were associated with improved tumor response to chemo-
therapy, but this was not statistically significant (OR 1.41,
95% CI 0.75–2.65).
In multivariate analysis, PS 1 (HR 1.39, 95% CI 1.07–1.80;
p¼ .013), shorter time from initial presentation with sarcoma
to starting palliative chemotherapy (HR 1.43, 95% CI
1.02–2.00; p¼ .020), and presence of bone metastases (HR
1.45, 95% CI 1.01–2.09; p¼ .046) were associated with
reduced OS. However, only bone metastases remained statis-
tically significant (HR 1.56, 95% CI 1.16–2.09; p¼ .003) in the
final reduced model (Table 3).
Table 1. Patient characteristics.
Analysis population
All patients (N¼ 455) All eligible patients (N¼ 310)
Characteristics n (%) n (%)
Treatment
Doxorubicin 228 (50.1) 156 (50.3)
Doxorubicinþ ifosfamide 227 (49.9) 154 (49.7)
Gender
Male 217 (47.7) 148 (47.7)
Female 238 (52.3) 162 (52.3)
Age
<40 years 112 (24.6) 73 (23.5)
40–49 years 148 (32.5) 94 (30.3)
50 years 195 (42.9) 143 (46.1)
PS
0 252 (55.4) 176 (56.8)
1 201 (44.2) 134 (43.2)
2 2 (0.4) 0 (0.0)
Time since initial diagnosis
<3 months 156 (34.3) 95 (30.6)
3–12 months 128 (28.1) 96 (31.0)
>12 months 171 (37.6) 119 (38.4)
Tumor grade (central review)
I 18 (4.0) 0 (0.0)
II 131 (28.8) 128 (41.3)
III 190 (41.8) 182 (58.7)
Not assessed/unknown 116 (25.5) 0 (0.0)
Histological subtype (central review)
Liposarcoma 34 (7.5) 25 (8.1)
Leiomyosarcoma 85 (18.7) 74 (23.9)
Synovial sarcoma 54 (11.9) 52 (16.8)
UPS 58 (12.7) 55 (17.7)
Other 117 (25.7) 104 (33.5)
Not a sarcoma 6 (1.3) 0 (0.0)
Missing 101 (22.2) 0 (0.0)
Primary tumor site involved 214 (47.0) 133 (42.9)
Liver metastases 80 (17.6) 53 (17.1)
Lung metastases 310 (68.1) 227 (73.2)
Bone metastases 65 (14.3) 44 (14.2)
Other sites of metastases 270 (59.3) 185 (59.7)
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Predictive factor analysis
Tumour grade (Grade II or III) and histological subtype,
grouped into liposarcoma, leiomyosarcoma, synovial sarcoma,
UPS, or ‘other’, were assessed as predictive factors. Outcomes
differed depending on local or central pathology assignment
of histological subtype (Table 4). By local pathology assess-
ment of histology, synovial sarcomas and ‘other’ subgroups
had a higher response rate with combination chemotherapy
compared to single-agent doxorubicin [43.5 versus 11.1% (OR
6.15, 95% CI 1.43–26.39) and 29.0 versus 10.5% (OR 3.48,
95% CI 1.27–9.53) for synovial sarcoma and ‘other’,
Table 2. Prognostic factors for best overall response (CRþ PR): multivariate analysis stratified by treatment.
Full multivariate model Reduced model stepwise selection
Parameter Levels OR (95% CI) p value OR (95% CI) p value
Gender Male 1.00 .231
Female 1.46 (0.78, 2.73)
Age <40 years 1.00 .653
40–49 years 1.20 (0.51, 2.82)
50 years 0.85 (0.36, 2.03)
PS 0 1.00 .992
1 1.00 (0.54, 1.83)
Time since initial diagnosis <3 months 1.00 .782
3–12 months 0.75 (0.33, 1.73)
>12 months 0.91 (0.40, 2.04)
Histological grade (central review) II 1.00 .287
III 1.41 (0.75, 2.65)
Histological subtype (central review) Liposarcoma 1.00 .007 1.00 .014
Leiomyosarcoma 0.15 (0.05, 0.50) 0.21 (0.08, 0.64)
Synovial sarcoma 0.20 (0.06, 0.64) 0.30 (0.11, 0.84)
UPS 0.21 (0.07, 0.65) 0.29 (0.10, 0.81)
Other 0.14 (0.05, 0.40) 0.19 (0.07, 0.50)
Primary tumor site involved No 1.00 .098
Yes 0.55 (0.27, 1.12)
Liver metastases No 1.00 .177
Yes 0.52 (0.20, 1.34)
Lung metastases No 1.00 .138
Yes 1.86 (0.82, 4.23)
Bone metastases No 1.00 .361
Yes 1.50 (0.63, 3.59)
Other sites of metastases No 1.00 .034 1.00 .006
Yes 0.51 (0.28, 0.95) 0.42 (0.23, 0.78)
(CRþ PR)¼ (complete responseþ partial response).
p values < .05 are highlighted in bold.
Table 3. Prognostic factor analysis for OS: multivariate analysis stratified by treatment.
Full multivariate model Reduced model stepwise selection
Parameter Levels HR (95% CI) p value HR (95% CI) p value
Gender Male 1.00 .058
Female 0.78 (0.60, 1.01)
Age <40 years 1.00 .553
40–49 years 1.15 (0.79, 1.68)
50 years 1.23 (0.85, 1.79)
PS 0 1.00 .013
1 1.39 (1.07, 1.80)
Time since initial diagnosis <3 months 1.00 .020
3–12 months 1.43 (1.02, 2.00)
>12 months 0.96 (0.68, 1.34)
Histological grade (central review) II 1.00 .257
III 1.16 (0.90, 1.50)
Histological subtype (central review) Liposarcoma 1.00 .281
Leiomyosarcoma 1.80 (1.04, 3.12)
Synovial sarcoma 1.58 (0.88, 2.82)
UPS 1.77 (1.02, 3.09)
Other 1.72 (1.03, 2.88)
Primary tumor site involved No 1.00 .999
Yes 1.00 (0.74, 1.34)
Liver metastases No 1.00 .294
Yes 1.20 (0.85, 1.70)
Lung metastases No 1.00 .838
Yes 1.03 (0.77, 1.39)
Bone metastases No 1.00 .046 1.00 .003
Yes 1.45 (1.01, 2.09) 1.56 (1.16, 2.09)
Other sites of metastases No 1.00 .344
Yes 1.13 (0.87, 1.47)
p values < .05 are highlighted in bold.
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respectively], whilst tumor response rates for liposarcoma,
leiomyosarcoma and UPS subgroups did not differ signifi-
cantly by treatment arm. In contrast, by central pathology
assessment, the UPS subgroup had a higher response rate
with combination chemotherapy than with single-agent
doxorubicin [42.3 versus 6.9% (OR 9.90, 95% CI 1.93–50.7)],
but response did not differ significantly between treatment
arms for liposarcoma, leiomyosarcoma, synovial sarcoma or
‘other’ subgroups. Analysis of OS by local pathology assess-
ment showed no interaction between histological subgroup
and treatment arm, whilst patients with UPS by central path-
ology review had improved OS with combination chemother-
apy compared with single-agent doxorubicin (HR 0.44, 95%
CI 0.26–0.79) (Figure 2).
Irrespective of local or central pathology assessment,
Grade III tumors had an improved response rate with com-
bination chemotherapy compared with single-agent doxo-
rubicin (OR 2.93, 95% CI 1.30–6.61 and 3.64, 95% CI
1.72–7.70 by local and central pathology assessment, respect-
ively). Response rate in Grade II tumors by either local or
central pathology assessment did not differ significantly by
treatment arm. No interaction between treatment arm and
tumor grade was identified in OS analysis, irrespective of
local or central pathology assessment of grade.
Discussion
The EORTC 62012 was a multi-centre randomized Phase III
trial of first-line single-agent doxorubicin versus intensified
doxorubicin–ifosfamide chemotherapy for young, fit patients
with advanced intermediate or high-grade STS [5]. Patients
were enrolled and the results of study reported based on
local pathology assessment. We observed a substantial dis-
cordance between local pathology assessment and central
pathology expert review of histological subtype and tumor
grade. This degree of discordance is consistent with levels
reported by other STS studies [9–13]. STS pathology is highly
complex, and the classifications of STS subtypes are con-
stantly evolving. Despite the growing role of molecular path-
ology to facilitate diagnosis, the identification of STS
subtypes still largely relies on interpretation of tumor morph-
ology and immunohistochemistry. Central pathology
review fulfills an important role in verifying the local path-
ology diagnosis. However, central pathology assessment is
wholly dependent on the specimen submitted for review.
In contrast, local pathology opinion may be refined by access
to additional tumor samples and to clinical and radiological
correlates. STS tumors contain areas of heterogeneity, and
this may explain some of the discordance we observed
between local and central pathology opinions.
Previously, clinical trials in STS included patients with a
variety of different histological subtypes. As treatments of
individual subtypes are progressively refined, clinical trials
increasingly recruit patients with specific STS histological sub-
types. The EORTC 62043 study, a single-arm Phase II trial of
pazopanib in patients with advanced STS, e.g., assessed treat-
ment response in four histological cohorts of STS (leiomyo-
sarcoma, liposarcoma, synovial sarcoma and ‘others’) [14]. On
the basis of this study, patients with liposarcoma were
excluded from the subsequent licensing Phase III PALETTE
trial [15]. Different conclusions could be drawn from our sub-
group analysis of histological subtype as a predictive factor
of response to combination chemotherapy in the EORTC
62012 study, dependent on whether local pathology or cen-
tral pathology assessment of tumor histology was used. This
analysis was exploratory, and was limited by small numbers
of patients in each histological subgroup, but it highlights
the importance of accurate pathology classification in STS
studies to the interpretation of trial results. Local pathology
assessment and central pathology review perform comple-
mentary functions, and our analysis suggests a role for incor-
porating mandatory prospective central pathology review
into future trial protocols. This should become possible in
practice as shared digital platforms become increasingly
common.
Our analysis suggested that UPS, synovial sarcoma and
‘other’ histological subtypes were most likely to respond to
treatment with combination chemotherapy. The histological
subgroup labeled ‘other’ encompassed a pooled collection of
rarer STS subtypes with diverse pathologies. Together, this
subgroup represented a third (104/310) of all patients
included in this analysis, which individually were too infre-
quent to be analyzed separately. Only UPS by central review
classification had improved OS with combination chemother-
apy. Interestingly, a contemporary study of peri-operative
epirubicinþ ifosfamide chemotherapy in localized high-risk
STS of the trunk and extremities also reported improved OS
outcomes in UPS compared to other histological subtypes
[16]. The lack of OS advantage with combination chemother-
apy in synovial sarcoma and ‘other’ subtypes despite
Table 4. Interaction of histological subtype on response to treatment (A: local pathology assessment; B: central pathology assessment).
Histological subtype
(local)
Total (N¼ 310),
n (%)
Doxo responders
(N¼ 22), n (row %)
Total (N¼ 156),
n (column %)
DxIf responders
(N¼ 44), n (row %)
Total (N¼ 154),
n (column %) OR (95% CI)
A
Liposarcoma 31 (10) 6 (37.5) 16 (10.3) 5 (33.3) 15 (9.7) 0.83 (0.19, 3.64)
Leiomyosarcoma 80 (26) 4 (10.5) 38 (24.4) 9 (21.4) 42 (27.3) 2.32 (0.65, 8.27)
Synovial sarcoma 50 (16) 3 (11.1) 27 (17.3) 10 (43.5) 23 (14.9) 6.15 (1.43, 26.39)
UPS 30 (10) 3 (16.7) 18 (11.5) 2 (16.7) 12 (7.8) 1.00 (0.14, 7.10)
Other 119 (38) 6 (10.5) 57 (36.5) 18 (29.0) 62 (40.3) 3.48 (1.27, 9.53)
B
Liposarcoma 25 (8) 7 (50.0) 14 (9.0) 5 (45.5) 11 (7.1) 0.83 (0.17, 4.06)
Leiomyosarcoma 74 (24) 4 (12.5) 32 (20.5) 8 (19.0) 42 (27.3) 1.65 (0.45, 6.05)
Synovial sarcoma 52 (17) 4 (16.0) 25 (16.0) 9 (33.3) 27 (17.5) 2.63 (0.69, 9.98)
UPS 55 (18) 2 (6.9) 29 (18.6) 11 (42.3) 26 (16.9) 9.90 (1.93, 50.7)
Other 104 (33) 5 (8.9) 56 (35.9) 11 (22.9) 48 (31.2) 3.03 (0.97, 9.47)
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improved tumor response rates is consistent with a separate
analysis of the EORTC 62012 study, which demonstrated that
the absence of tumor progression and not the extent of dis-
ease remission defines prognosis in STS [17]. Synovial sarco-
mas are considered to be chemosensitive tumors. Previous
studies have suggested that synovial sarcomas have higher
responses rates to chemotherapy than other STS subtypes,
including improved response rates to regimens containing
ifosfamide [18]. UPS are aggressive high-grade tumors with no
discernable histological differentiation [19]. They are diag-
nosed by exclusion of other pleomorphic subtypes, including
leiomyosarcoma and liposarcoma. Samples identified as UPS
on central pathology review therefore include poorly differen-
tiated STS subtypes, which have been re-classified on the basis
of the submitted specimen. Such poorly differentiated tumors
may have aggressive tumor biology that benefit more from
combination chemotherapy. This would support the parallel
observation that high-grade tumors were more likely to
respond to combination chemotherapy than intermediate-
grade lesions, although tumor grade did not influence OS.
We used central pathology assessment of tumor histology
and tumor grade for the prognostic factor analysis, as this
had been undertaken by a small panel of expert sarcoma
pathologists. The prognostic factor analysis identified that
liposarcoma histology was associated with improved tumor
response rate compared to other histological subgroups.
Previous studies have also suggested that liposarcomas are
associated with a higher response rate [6]. The liposarcoma
subgroup consisted of disparate subtypes including dediffer-
entiated liposarcoma, pleomorphic liposarcoma and myxoid
liposarcoma. Myxoid liposarcomas are considered chemosen-
sitive, whilst dedifferentiated liposarcomas are considered
less sensitive to chemotherapy. Unfortunately, the specific
liposarcoma subtype present was not recorded centrally, and
analysis to refine tumor response rate by liposarcoma sub-
type was not possible, although the small number of liposar-
coma patients included in the study (25 cases by central
pathology review) would have limited more detailed analysis.
We identified that the presence of metastases at sites
other than lung, liver and bone was associated with poorer
response to chemotherapy. In our study population, ‘other’
sites of metastatic disease were involved in almost 60% of
cases. Previous large database studies of response to first-line
palliative chemotherapy in advanced STS have reported the
presence of metastatic disease at sites other than lung, liver
and bone in 35% of cases [20,21], and have identified the
presence of disease at ‘other’ metastatic sites as prognostic
for adverse OS [20].
Figure 2. Interaction of histological subtype with treatment on OS (A: central pathology review; B: local pathology review).
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PS is a well-established prognostic factor [20]. The EORTC
62012 study recruited patients aged 60 years with WHO PS
0 or 1. It is therefore striking that PS was prognostic of OS
despite eligibility criteria restricting the study population to
young fit patients. Time between initial diagnosis of sarcoma
and commencing palliative chemotherapy has previously
been identified as prognostic [6]. Patients with a shorter time
to starting palliative chemotherapy from initial diagnosis
(3–12 months) had worse OS. This cohort consisted of
patients with poor tumor biology and rapidly progressive dis-
ease. A longer interval between initial diagnosis and starting
chemotherapy (>12 months) implied less aggressive disease
and was associated with improved OS, whilst patients pre-
senting with metastatic disease (interval from initial diagnosis
<3 months) represented a mix of these two patient popula-
tions. The presence of bone metastases was the only factor
prognostic for OS in the final multivariate model. Bone meta-
stases were reported in 44/310 (14.1%) patients included in
the subgroup analysis. A previous multi-centre retrospective
analysis identified bone metastases as a poor prognostic fea-
ture, and suggested routine use of bisphosphonate therapy
for patients with metastatic bone disease to delay the onset
of skeletal related events (e.g., pathological fracture, spinal
cord compression or hypercalcaemia) [22].
In summary, we performed an analysis of the EORTC
62012 study, a large Phase III trial of single-agent doxorubicin
versus a doxorubicin–ifosfamide combination for advanced
STS. This subgroup analysis highlights the importance of the
sarcoma pathologist to the assessment of clinical trial out-
comes. Single-agent doxorubicin remains standard of care
first-line chemotherapy for patients with advanced STS.
However, combination doxorubicin–ifosfamide is indicated
for selected patients, and this analysis suggests combination
treatment may be most appropriate to consider in patients
60 years old, PS 0 or 1, with poorly differentiated Grade III
tumors including UPS.
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